Clinicopathologic features and oncologic outcomes of colorectal cancer patients with extremely high carcinoembryonic antigen
- PMID: 25367182
- DOI: 10.1007/s00384-014-2053-1
Clinicopathologic features and oncologic outcomes of colorectal cancer patients with extremely high carcinoembryonic antigen
Abstract
Purpose: The aim of this study is to investigate the clinicopathologic features and oncologic outcomes of colorectal cancer patients with extremely elevated (≥50 ng/mL) preoperative serum carcinoembryonic antigen (CEA) levels.
Methods: We enrolled 756 primary colorectal cancer patients with elevated preoperative CEA levels (≥5 ng/mL) who underwent surgery between 2004 and 2010 and compared clinicopathologic features according to preoperative CEA levels of 5-50 ng/mL (n = 676) and ≥50 ng/mL (n = 80). The impact of extremely elevated CEA on overall survival (OS) and disease-free survival (DFS) was analyzed using Kaplan-Meier analysis and the Cox proportional hazards model.
Results: The median follow-up period was 43 months (range, 0-121). Patients with preoperative CEA ≥50 ng/mL demonstrated higher rates of advanced T stage (97.3 vs. 88.6%, p = 0.016) and distant metastasis (33.8 vs. 17.9%, p = 0.002), but not lymph node metastasis (54.1 vs. 52.2%, p = 0.807). The 5-year OS rate was 69.1%, and the 3-year DFS rate of curatively resected patients (n = 641; 84.8%) was 68.9%. In multivariate analysis, preoperative CEA ≥50 ng/mL, as well as age, N stage, vascular invasion, perineural invasion, post/preoperative CEA ratio ≥0.32, and palliative resection, was an independent predictor of OS. However, for patients treated with curative resection, preoperative CEA ≥50 ng/mL was not significantly associated with DFS or OS (p = 0.053 and 0.157, respectively).
Conclusions: Colorectal cancer patients with extremely elevated (≥50 ng/mL) preoperative CEA had advanced disease more frequently but comparable oncologic outcomes if curative resection was performed.
Similar articles
-
Prognostic impact of carcinoembryonic antigen and carbohydrate antigen 19-9 in stage IV colorectal cancer patients after R0 resection.J Surg Res. 2016 Oct;205(2):384-392. doi: 10.1016/j.jss.2016.06.078. Epub 2016 Jul 4. J Surg Res. 2016. PMID: 27664887
-
Prognostic value of preoperative carcinoembryonic antigen/tumor size in rectal cancer.World J Gastroenterol. 2019 Sep 7;25(33):4945-4958. doi: 10.3748/wjg.v25.i33.4945. World J Gastroenterol. 2019. PMID: 31543685 Free PMC article.
-
Factors predicting long-term survival in colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen.J Cancer Res Clin Oncol. 2013 Sep;139(9):1449-55. doi: 10.1007/s00432-013-1459-4. Epub 2013 Jun 14. J Cancer Res Clin Oncol. 2013. PMID: 23765330 Free PMC article.
-
Value of carcinoembryonic antigen in the management of colorectal cancer.Dis Colon Rectum. 1994 Mar;37(3):272-7. doi: 10.1007/BF02048166. Dis Colon Rectum. 1994. PMID: 8137675 Review.
-
A Review of the Role of Carcinoembryonic Antigen in Clinical Practice.Ann Coloproctol. 2019 Dec;35(6):294-305. doi: 10.3393/ac.2019.11.13. Epub 2019 Dec 31. Ann Coloproctol. 2019. PMID: 31937069 Free PMC article. Review.
Cited by
-
Clinical significance of detecting circulating tumor cells in colorectal cancer using subtraction enrichment and immunostaining-fluorescence in situ hybridization (SE-iFISH).Oncotarget. 2017 Mar 28;8(13):21639-21649. doi: 10.18632/oncotarget.15452. Oncotarget. 2017. PMID: 28423493 Free PMC article.
-
Combination of Geriatric Nutritional Risk Index and Carcinoembryonic Antigen to Predict the Survival of Patients With Colorectal Cancer.Front Nutr. 2022 Jun 30;9:902080. doi: 10.3389/fnut.2022.902080. eCollection 2022. Front Nutr. 2022. PMID: 35845803 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical